애로우헤드 파마슈티컬스, Inc.
US ˙ NasdaqGS ˙ US04280A1007

SecurityARWR / Arrowhead Pharmaceuticals, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership3,701 shares
Latest Disclosed Value $ 58,475
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 8.48% decrease in ownership of ARWR / Arrowhead Pharmaceuticals, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 3,701 shares of Arrowhead Pharmaceuticals, Inc. (US:ARWR) valued at $58,476 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 4,044 shares of Arrowhead Pharmaceuticals, Inc.. This represents a change in shares of -8.48% during the quarter. The current value of the position is $278,167 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,701 -343 -8.48 58 13.73 0.6499
2025-05-29 2025-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 4,044 687 20.46 52 -19.05 0.5473
2025-03-03 2024-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,357 -519 -13.39 63 -16.00 0.6327
2024-11-29 2024-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,876 368 10.49 75 -17.58 0.6800
2024-08-29 2024-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,508 -99 -2.74 91 -11.65 0.8312
2024-05-30 2024-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,607 -70 -1.90 103 -8.04 0.8749
2024-02-29 2023-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,677 45 1.24 113 15.46 0.9222
2023-11-29 2023-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,632 132 3.77 98 -21.77 0.8450
2023-08-28 2023-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,500 -813 -18.85 125 13.76 0.9849
2023-05-30 2023-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 4,313 -604 -12.28 110 -45.23 0.8298
2023-02-28 2022-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 4,917 888 22.04 199 49.62 1.2061
2022-11-29 2022-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 4,029 -378 -8.58 133 -14.19 0.9293
2022-08-29 2022-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 4,407 437 11.01 155 -14.84 1.0645
2022-05-26 2022-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,970 107 2.77 183 -28.91 1.0789
2022-02-28 2021-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,863 126 3.37 256 9.87 1.1317
2021-11-29 2021-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,737 437 13.24 233 -14.65 0.9807
2021-08-27 2021-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 3,300 -534 -13.93 273 7.48 1.1447
2021-05-27 2021-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,834 69 1.83 254 -11.81 1.1440
2021-03-01 2020-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 3,765 -2,784 -42.51 289 2.49 1.1765
2020-11-25 2020-09-30 NP Arrowhead Pharmaceuticals EC US04280A1007 6,549 -556 -7.83 282 -8.17 1.1770
2020-08-27 2020-06-30 NP Arrowhead Pharmaceuticals EC US04280A1007 7,105 2,148 43.33 307 115.49 1.2367
2020-06-01 2020-03-31 NP Arrowhead Pharmaceuticals EC US04280A1007 4,957 -317 -6.01 143 -57.49 0.8729
2020-03-02 2019-12-31 NP Arrowhead Pharmaceuticals EC US04280A1007 5,274 5,274 335 1.5485
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.